ESMO clinical recommendationsSoft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Cited by (0)
Approved by the ESMO Guidelines Working Group: August 2003, last update February 2009. This publication supercedes the previously published version—Ann Oncol 2008; 19 (Suppl 2): ii89–ii93.
Conflict of interest: Dr Casali has reported that he received honoraria and travel coverage for medical meetings from PharmaMar. He had a consultancy role with Ariad Merck, Glaxo and Sanofi Aventis. He is currently conducting research sponsored by PharmaMar, Ariad Merck, Johnson & Johnson, Glaxo and Sanofi Aventis. Dr Jost and Dr Sleijfer have reported no conflicts of interest. Dr Verweij has not reported any conflicts of interest. Prof. Blay has reported that he is currently conducting research sponsored by Novartis, Pfizer, GSK, Pharmamar, Roche and that he received honoraria and research grants from these companies, He has also reported that he is a member of the speakers' bureau for Novartis and Pfizer.